$SYRS Announces Clinical Data from Ongoing PhaseÂ2 Trial of SY1425 in Genomically Defined AML and MDS Patients ASH18 httpswww.businesswire.comnewshome20181202005039enSyrosAnnouncesPromisingClinicalDataOngoingPhaseC2A02.XAQQHbKsOkY.twit

$SYRS Announces Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients #ASH18 https://www.businesswire.com/news/home/20181202005039/en/Syros-Announces-Promising-Clinical-Data-Ongoing-Phase%C2%A02#.XAQQHbKsOkY.twit

12:02 EST 2 Dec 2018 | Odi Bruckman

$SYRS Announces Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients #ASH18 https://www.businesswire.com/news/home/20181202005039/en/Syros-Announces-Promising-Clinical-Data-Ongoing-Phase%C2%A02#.XAQQHbKsOkY.twitter …

More From BioPortfolio on "$SYRS Announces Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients #ASH18 https://www.businesswire.com/news/home/20181202005039/en/Syros-Announces-Promising-Clinical-Data-Ongoing-Phase%C2%A02#.XAQQHbKsOkY.twit"